Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
暂无分享,去创建一个
A. Levis | D. Cilloni | S. Galimberti | G. Palumbo | M. Petrini | I. Petrini | F. Guerrini | E. Messa | F. Salvi | D. Gioia
[1] Y. Ho,et al. Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways. , 2011, Chemico-biological interactions.
[2] P. Tchounwou,et al. Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells , 2010, Journal of hematology & oncology.
[3] Mario Petrini,et al. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. , 2010, Cancer genetics and cytogenetics.
[4] S. Galimberti,et al. WT1 expression levels at diagnosis could predict long‐term time‐to‐progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes , 2010, British journal of haematology.
[5] W. Hofmann,et al. Molecular mechanisms involved in the progression of myelodysplastic syndrome. , 2010, Future oncology.
[6] E. Thiel,et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.
[7] C. Tse,et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.
[8] Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. , 2008, Leukemia research.
[9] A. Verma,et al. Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment , 2008, Leukemia & lymphoma.
[10] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Kenific,et al. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. , 2006, Cancer research.
[12] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[13] H. Dombret,et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Hainsworth,et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Dörken,et al. Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway , 2005, Oncogene.
[16] B. Dörken,et al. Inhibition of NF- (cid:1) B essentially contributes to arsenic-induced apoptosis , 2003 .
[17] O. Sordet,et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes , 2000, Leukemia.
[18] S. Rafii,et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. , 2000, Blood.
[19] K. Bhalla,et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.
[20] R. Klein,et al. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases , 1999, Medical oncology.
[21] P. Greenberg,et al. Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.
[22] G. Wong,et al. Molecular cloning and expression of a receptor for human tumor necrosis factor , 1990, Cell.